Key Highlights

  • Loss was USD 0.81 per share against an estimated USD 0.85 loss, and Revenue of USD 0.585 million topped it.
  • The FDA approved ISEMBYLD on September 11, and first-quarter net product revenue was USD 0.6 million from initial inventory.
  • Cash, equivalents and marketable securities were USD 413.6 million, with a USD 205 million priority review voucher sale announced.
  • Research and development expense was USD 54.1 million and selling, general and administrative expense USD 52.5 million.

Scholar Rock (NASDAQ:SRRK) reported a third quarter 2026 loss of USD 0.81 per share, narrower than the USD 0.85 estimated loss. Revenue of USD 0.585 million exceeded the USD 0.304 million estimate. It was the company's first revenue quarter, reflecting USD 0.6 million of net product sales of ISEMBYLD, which the company said came from initial inventory shipped to its specialty network.

The FDA approved ISEMBYLD on Friday, September 11, ahead of its target action date. The therapy is indicated for patients with spinal muscular atrophy aged two and older who are receiving an SMN2-targeted treatment. In the Phase 3 SAPPHIRE study, it delivered a 2.2-point improvement in motor function on the Hammersmith Functional Motor Scale compared with an SMN2-targeted therapy alone.

The company estimates about 6,600 patients in the United States are receiving an SMN2-targeted therapy. In the first six weeks of launch, enrollments were balanced across regions, and more than one third of the top 140 treatment centers had enrolled patients, with a significant number of enrollments coming from other centers. Enrolled patients were spread across Evrysdi, Spinraza and high-dose Spinraza backgrounds, including some previously treated with Zolgensma.

Management said the time from prescription to infusion is running 60 to 90 days or longer at this early stage, so most patients enrolled through October are anticipated to begin infusions in 2027. Revenue in the near term therefore reflects inventory stocking more than infusion volume.

Financial Position

Research and development expense was USD 54.1 million, up USD 3.6 million or 7.2% from USD 50.5 million a year earlier. Selling, general and administrative expense was USD 52.5 million, down 1.1% from USD 53.1 million. Cost of product revenue was USD 8,000. The nine-month net loss was USD 322.6 million, and the accumulated Deficit was USD 1.6 billion.

Cash, cash equivalents and marketable securities were USD 413.6 million at September 30. The company announced a definitive agreement to sell its priority review voucher for USD 205 million, which management said adds to its financial position. The filing also states that existing resources and available Debt capacity are sufficient to fund operations for at least one year after the financial statements are issued. During the nine months, the company sold 3,543,692 shares under its at-the-market program for net proceeds of USD 160.8 million.

Regulatory Steps Outside the United States

The company's European application, which now includes an alternate Fill and finish facility, has been validated, and management anticipates a CHMP opinion in the first half of 2027. In early November it submitted a Japanese application two months ahead of its guidance. That application was accepted under priority review, and management anticipates a Japan launch near the end of 2027 pending approval.

Items to Follow

Infusion starts as enrollments convert, the first full quarter of sales, the European opinion in the first half of 2027 and the Japanese review are the dated or measurable items. Spending levels relative to revenue are the financial marker.